Jean Luc Harousseau

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. doi request reprint Integrating novel therapies in the transplant paradigm
    Jean Luc Harousseau
    Cancer Center René Gauducheau, Bd J Monod, 44805 Nantes Saint Herblain, France
    Cancer J 15:479-84. 2009
  2. doi request reprint Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials
    Jean Luc Harousseau
    Centre René Gauducheau Bd Jacques Monod 44850 St Herblain, Nantes, France
    J Clin Oncol 27:5720-6. 2009
  3. doi request reprint A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
    Jean Luc Harousseau
    University Hospital Hotel Dieu, Nantes, France
    Blood 114:1166-73. 2009
  4. doi request reprint The role of complete response in multiple myeloma
    Jean Luc Harousseau
    Centre Rene Gauducheau, Bd Jacques Monod 44850, St Herblain, France
    Blood 114:3139-46. 2009
  5. ncbi request reprint Hematopoietic stem cell transplantation in multiple myeloma
    Jean Luc Harousseau
    Rene Gauducheau Cancer Center, 44805 Nantes, Saint Herblain, France
    J Natl Compr Canc Netw 7:961-70. 2009
  6. pmc Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
    Jean Luc Harousseau
    Centre Rene Gauducheau, bd Jacques Monod, Nantes, St Herblain, France
    Haematologica 95:1738-44. 2010
  7. doi request reprint Clinical management of myeloma--state of the art
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    Cancer Treat Rev 36:S1-2. 2010
  8. doi request reprint Optimising patient outcomes in myeloma
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    Cancer Treat Rev 36:S33-5. 2010
  9. doi request reprint Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    J Clin Oncol 28:4621-9. 2010
  10. doi request reprint Ten years of improvement in the management of multiple myeloma: 2000-2010
    Jean Luc Harousseau
    Rene Gauducheau Cancer Center, Boulevard Jacques Monod, Nantes St Herblain, France
    Clin Lymphoma Myeloma Leuk 10:424-42. 2010

Detail Information

Publications63

  1. doi request reprint Integrating novel therapies in the transplant paradigm
    Jean Luc Harousseau
    Cancer Center René Gauducheau, Bd J Monod, 44805 Nantes Saint Herblain, France
    Cancer J 15:479-84. 2009
    ..On the other hand, results obtained with novel agents are attractive as well and randomized studies comparing novel agents plus early ASCT versus novel agents plus ASCT at progression are planned...
  2. doi request reprint Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials
    Jean Luc Harousseau
    Centre René Gauducheau Bd Jacques Monod 44850 St Herblain, Nantes, France
    J Clin Oncol 27:5720-6. 2009
    ..The purpose of this study was to analyze the prognostic impact of very good partial response (VGPR) in patients treated with high-dose therapy...
  3. doi request reprint A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
    Jean Luc Harousseau
    University Hospital Hotel Dieu, Nantes, France
    Blood 114:1166-73. 2009
    ..The results of this randomized study showed that tipifarnib treatment did not result in an increased survival compared with BSC, including hydroxyurea. This trial was registered at www.clinicaltrials.gov as #NCT00093990...
  4. doi request reprint The role of complete response in multiple myeloma
    Jean Luc Harousseau
    Centre Rene Gauducheau, Bd Jacques Monod 44850, St Herblain, France
    Blood 114:3139-46. 2009
    ..Finally, there are several levels of CR and in the future it will be necessary to confirm the prognostic impact of immunophenotypic or molecular CR or of CR defined by imaging procedures...
  5. ncbi request reprint Hematopoietic stem cell transplantation in multiple myeloma
    Jean Luc Harousseau
    Rene Gauducheau Cancer Center, 44805 Nantes, Saint Herblain, France
    J Natl Compr Canc Netw 7:961-70. 2009
    ....
  6. pmc Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
    Jean Luc Harousseau
    Centre Rene Gauducheau, bd Jacques Monod, Nantes, St Herblain, France
    Haematologica 95:1738-44. 2010
    ....
  7. doi request reprint Clinical management of myeloma--state of the art
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    Cancer Treat Rev 36:S1-2. 2010
    ....
  8. doi request reprint Optimising patient outcomes in myeloma
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    Cancer Treat Rev 36:S33-5. 2010
    ..Treatment of MM should therefore be tailored to the individual patient based on the goals of therapy, patient condition, expected adverse events, and patient preference...
  9. doi request reprint Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    J Clin Oncol 28:4621-9. 2010
    ..To compare efficacy and safety of bortezomib plus dexamethasone and vincristine plus doxorubicin plus dexamethasone (VAD) as induction before stem-cell transplantation in previously untreated myeloma...
  10. doi request reprint Ten years of improvement in the management of multiple myeloma: 2000-2010
    Jean Luc Harousseau
    Rene Gauducheau Cancer Center, Boulevard Jacques Monod, Nantes St Herblain, France
    Clin Lymphoma Myeloma Leuk 10:424-42. 2010
    ....
  11. doi request reprint Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    Blood 116:3743-50. 2010
    ..These results highlight that CR is an important treatment goal and support prolonged VMP therapy to achieve maximal response. This study is registered at http://www.clinicaltrials.gov as NCT00111319...
  12. ncbi request reprint Multiple myeloma in the elderly: when to treat, when to go to transplant
    Jean Luc Harousseau
    Rene Gauducheau Cancer Center, Nantes Saint Herblain, France
    Oncology (Williston Park) 24:992-8. 2010
    ..However, considering the progress in non-intensive therapy, autologous transplantation should not currently be offered to elderly patients outside of a clinical trial...
  13. doi request reprint Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)
    Herve Avet-Loiseau
    Centre Hospitalier Universitaire, Nantes, France
    J Clin Oncol 28:4630-4. 2010
    ..Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is able to overcome these prognostic parameters...
  14. ncbi request reprint Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
    Frederic Garban
    Hematology Department, University Hospital Hotel Dieu, Place Ricordeau, 44093 Nantes Cedex 01, France
    Blood 107:3474-80. 2006
    ..2 vs 35 months; P = .07). In patients with high-risk de novo MM, the combination of ASCT followed by dose-reduced allogeneic transplantation was not superior to tandem dose-intensified, melphalan-based ASCT...
  15. ncbi request reprint Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Place Alexis Ricordeau, 44093 Nantes Cedex 01, France
    Blood 107:397-403. 2006
    ..39). In high-risk patients the dose intensity of melphalan at 420 mg/m2 led to encouraging results, but the addition of anti-IL-6 monoclonal antibody to the second conditioning regimen did not improve either OS nor EFS...
  16. ncbi request reprint Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Fra
    Philippe Moreau
    Service d Hematologie, University Hospital Hotel Dieu, Place Alexis Recordeau, 44093 Nantes Cedex 01, France
    Blood 99:731-5. 2002
    ..This regimen should be considered as the standard of care before autologous stem cell transplantation in multiple myeloma...
  17. doi request reprint Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
    Philippe Moreau
    University Hospital, Nantes, France
    Blood 118:5752-8; quiz 5982. 2011
    ..001). vtD, including reduced doses of bortezomib and thalidomide, yields higher VGPR rates compared with VD and can be considered a new effective triplet combination before HDT/ASCT...
  18. doi request reprint Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma
    Aline Clavert
    Service d Hematologie Clinique, Centre Hospitalier et Universitaire CHU de Nantes, Nantes, France
    Leuk Lymphoma 51:1502-8. 2010
    ..We conclude that RIC allo-SCT after auto-SCT is feasible and a potentially efficient therapy for relapsed or transformed aggressive B-cell NHL, warranting further prospective evaluation...
  19. ncbi request reprint Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma
    Nicolas Blin
    Haematology Department, University Hospital Hotel Dieu, Place Alexis Ricordeau, Nantes Cedex, France
    Leuk Lymphoma 45:2161-3. 2004
    ..The patient died 1 week after the diagnosis of mucormycosis despite the administration of liposomal amphotericin B. The role of voriconazole and caspofungin in the emergence of mucormycosis is discussed...
  20. ncbi request reprint Evolving role of stem cell transplantation in multiple myeloma
    Jean Luc Harousseau
    Department of Hematology, University Hospital Hotel Dieu, 1 Place Alexis Ricordeau, 44035 Nantes, France
    Clin Lymphoma Myeloma 6:89-95. 2005
    ..Allogeneic stem cell transplantation should be proposed only in the context of a clinical trial...
  21. ncbi request reprint Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma
    Philippe Moreau
    Department of Clinical Hematology, University Hospital, Nantes, France
    Haematologica 89:547-51. 2004
    ..The aims of this study were to confirm this hypothesis and to test the prognostic value of CD45 expression in newly diagnosed MM patients...
  22. doi request reprint Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies
    Florent Malard
    Centre Hospitalier et Universitaire CHU de Nantes, Service d Hematologie Clinique, Nantes, France
    Biol Blood Marrow Transplant 17:1698-703. 2011
    ..18), suggesting that reduced-intensity conditioning (RIC) based on Flu, very low-dose BU, and ATG has the potential to induce long-term remissions in patients with lymphoid malignancies...
  23. ncbi request reprint Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support
    Noel Milpied
    University Hospital of Nantes, Nantes, France
    N Engl J Med 350:1287-95. 2004
    ..The efficacy of first-line intensive chemotherapy plus transplantation of autologous hematopoietic stem cells in adults with disseminated aggressive lymphoma is unknown...
  24. doi request reprint Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression
    Patrice Chevallier
    Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
    Int J Hematol 88:209-11. 2008
    ..Here we report the case of a 30-year-old man with a refractory CD33+ ALL who received a salvage regimen combining chemotherapy + GO and achieved a transient CR...
  25. ncbi request reprint Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
    Philippe Moreau
    Clinical Hematology Department and the Hematology Laboratory, University Hospital, Nantes, France
    Blood 100:1579-83. 2002
    ..These data emphasized the interest in analyzing these two translocations by fluorescence in situ hybridization in prospective therapeutic trials in order to consider these translocations as distinct entities...
  26. doi request reprint Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation
    Florent Malard
    Centre Hospitalier et Universitaire CHU de Nantes, Service d Hematologie Clinique, Nantes, France
    Biol Blood Marrow Transplant 16:28-34. 2010
    ..014). We conclude that precise monitoring of CsA concentrations and adjustment of CsA dose early after allo-SCT may be effective to prevent onset of severe aGVHD...
  27. ncbi request reprint Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells
    Emmanuelle Menoret
    Institut National de la Sante et de la Recherche Medicale, Unite 601, Nantes, F 44000, France
    Blood 108:1346-52. 2006
    ..Taken together, our data clearly encourage clinical trials of anti-TRAILR1 mAb in multiple myeloma, especially for patients whose disease is in relapse, at the time of drug resistance...
  28. ncbi request reprint CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
    Nelly Robillard
    Laboratory of Hematology and Institut National de la Santé et de la Recherche Médicale INSERM U463, Institute of Biology, Nantes, France
    Blood 102:1070-1. 2003
    ..0001). In conclusion, CD20 expression is associated with small mature plasma cell morphology and with t(11;14) in patients with MM...
  29. ncbi request reprint Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?
    Pierre Peterlin
    Department of Haematology, CHU de Nantes, Nantes, France
    Transplantation 94:295-301. 2012
    ..Impact of total-body irradiation (TBI) in conditioning regimen on outcome for patients with mantle cell lymphoma (MCL) remains unknown...
  30. ncbi request reprint FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease
    Solene Querellou
    Department of Nuclear Medicine, Hospital of the University of Nantes, Place Alexis Ricordeau, 44093, Nantes, France
    Ann Hematol 85:759-67. 2006
    ..04) for NHL, and EFS (p < 0.0001) for HD (but not for OS, because no HD patient died). FDG-PET at mid-treatment can predict the outcome of patients with aggressive lymphoma and should be a useful tool to modify an ineffective therapy...
  31. doi request reprint Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
    Herve Avet-Loiseau
    Hematology Laboratory, University Hospital, and Inserm U892, Nantes, France
    Blood 117:2009-11. 2011
    ..28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma...
  32. doi request reprint Proteasome inhibitors in multiple myeloma: 10 years later
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Nantes, France
    Blood 120:947-59. 2012
    ..This review provides an overview of the role of PIs in the treatment of MM, focusing on developments over the past decade...
  33. ncbi request reprint Role of bone marrow transplantation in the disease pathway of myeloma
    Jean Luc Harousseau
    Department of Hematology, Hotel Dieu, Nantes, France
    J Natl Compr Canc Netw 5:163-9. 2007
    ..Transplant-related mortality associated with this procedure is lower, but more follow-up is needed before definite conclusions can be drawn...
  34. ncbi request reprint Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity
    Patrice Chevallier
    Department of Hematology, Centre Hospitalier Universitaire, Nantes, France
    Leuk Res 32:1321-2. 2008
    ..Here we describe the case of a 69-year-old patient who achieved a second complete remission with this association without additional toxicity...
  35. ncbi request reprint The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy
    Regis Bataille
    INSERM, U601, Nantes, France
    Haematologica 91:1234-40. 2006
    ..Finally, this review presents data from normal PC up to human myeloma cell lines in order to: (i) define different entities of MM based on expression of CD19, CD20, CD27 and CD117; and (ii) identify new therapeutic targets...
  36. doi request reprint Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
    Philippe Moreau
    University Hospital, Nantes, France
    Lancet Oncol 12:431-40. 2011
    ..We compared the efficacy and safety of subcutaneous versus intravenous bortezomib at the approved 1·3 mg/m(2) dose and twice per week schedule in patients with relapsed multiple myeloma...
  37. ncbi request reprint Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease
    Florence Magrangeas
    INSERM U463, Department of Clinical Hematology, University Hospital, Nantes, France
    Blood 101:4998-5006. 2003
    ..This study shows that DNA microarrays enable us to perform a molecular dissection of the bioclinical diversity of MM and provide new molecular tools to investigate the pathogenesis of malignant plasma cells...
  38. ncbi request reprint Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level
    Florence Magrangeas
    Laboratory of Hematology, Clinical Hematology Department, University Hospital, Nantes, France
    Blood 103:3869-75. 2004
    ..Furthermore, it showed that this defect did not prevent the activation of the switch process because most of 14q32 translocations observed in LC MM occurred at switch regions...
  39. doi request reprint Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
    Philippe Moreau
    University Hospital, Nantes, France
    Blood 117:3041-4. 2011
    ..This study is registered with EudraCT (https://eudract.ema.europa.eu; EUDRACT 2005-000537-38) and http://clinicaltrials.gov (NCT00200681)...
  40. ncbi request reprint Stem-cell transplantation in multiple myeloma
    Jean Luc Harousseau
    Department of Hematology, Hotel Dieu, Nantes, France
    Best Pract Res Clin Haematol 18:603-18. 2005
    ..The results of allogeneic SCT remain disappointing due to a high transplant mortality. Strategies combining ASCT and reduced-intensity allogeneic SCT are currently being studied...
  41. ncbi request reprint CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis
    Regis Bataille
    INSERM UMR 601, Institute of Biology, Nantes, France
    Leuk Res 32:379-82. 2008
    ..In conclusion, CD117 (c-kit) is aberrantly expressed on a subset of MGUS and MM with a more indolent presentation and is functionally antinomic to CD221 (IGF-1R). CD117 expression could be related to a specific oncogenic pathway in MM...
  42. doi request reprint Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies
    Xavier Cahu
    CHU de Nantes, Service d Hematologie Clinique, Nantes, France
    Biol Blood Marrow Transplant 15:1531-7. 2009
    ..In conclusion, this data suggests that UCBT can be performed in adult patients with hematologic malignancies with an acceptable incidence of IRM provided a sufficient dose of nucleated cells is infused to the patient...
  43. pmc Prognostic significance of copy-number alterations in multiple myeloma
    Herve Avet-Loiseau
    L Institut National de la Santé et de la Recherche Médicale U892, Universite de Nantes, Institut de Biologie, 9 quai Moncousu, Nantes, 44093, France
    J Clin Oncol 27:4585-90. 2009
    ..Chromosomal aberrations are a hallmark of multiple myeloma but their global prognostic impact is largely unknown...
  44. doi request reprint Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia
    Patrice Chevallier
    Service d Hematologie Clinique, Centre Hospitalier Universitaire CHU Hotel Dieu, Nantes, France
    J Clin Oncol 26:5192-7. 2008
    ..To determine the antitumor activity and safety of a combination of gemtuzumab ozogamicin (GO), intermediate-dose cytarabine, and mitoxantrone (MIDAM) in patients with refractory or relapsed CD33(+) acute myeloid leukemia (AML)...
  45. doi request reprint Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies
    Philippe Moreau
    Centre Hospitalier Universitaire Nantes, Nantes, France
    J Clin Oncol 29:1898-906. 2011
    ....
  46. doi request reprint Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélom
    Olivier Decaux
    L Institut National de la Santé et de la Recherche Médicale, U892, University of Nantes, University, Hospital, Hematology Laboratory, Nantes, France
    J Clin Oncol 26:4798-805. 2008
    ..We used gene expression profiles of myeloma cells obtained at diagnosis to identify broadly applicable prognostic markers...
  47. ncbi request reprint Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required
    Stephane Vigouroux
    Service d Hematologie Clinique, CHU Hotel Dieu, Nantes, France
    Clin Infect Dis 40:e35-7. 2005
    ..An invasive infection was present in 3 patients who died soon after the diagnosis at 12, 13, and 45 days. Physicians should be mindful of this potential risk after treatment with voriconazole...
  48. ncbi request reprint A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
    Jean Luc Harousseau
    Service d Hematologie, Hotel Dieu, Nantes, France
    Blood 109:5151-6. 2007
    ..The response rate observed in this heavily pretreated group of patients suggests the requirement to enhance the response rate either by combining tipifarnib with other active agents or determining factors that are predictive of response...
  49. ncbi request reprint Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants
    Herve Avet-Loiseau
    Laboratory of Hematology, University Hospital, Nantes, France
    Blood 101:1570-1. 2003
    ..Thus, for unknown reasons, t(11;14) is the hallmark of IgM, IgE, and NS MM, (but not IgD MM), with a 5-fold increase of its incidence compared to that of IgG and IgA MM...
  50. pmc Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
    Laurence Lodé
    Laboratoire d Hematologie, University Hospital, Nantes, France
    Haematologica 95:1973-6. 2010
    ..In conclusion, we showed that 37% of the myeloma patients with del(17p) present a TP53 mutation versus 0% in patients lacking the del(17p). The prognostic significance of these mutations remains to be evaluated...
  51. doi request reprint Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
    Philippe Moreau
    Department of Hematology, University Hospital, Nantes, France
    Haematologica 93:1908-11. 2008
    ..Based on these exploratory findings, subcutaneous administration offers an alternative option to intravenous injection (ClinicalTrials.gov identifier: NCT00291538)...
  52. ncbi request reprint NK-KIR transcript kinetics correlate with acute graft-versus-host disease occurrence after allogeneic bone marrow transplantation
    Laure Denis
    HLA Laboratory, EFS Pays de Loire, Nantes, France
    Hum Immunol 66:447-59. 2005
    ..025). Thus determining the kinetics of KIR transcription should make it possible to identify transplanted patients at a high risk of developing aGvHD...
  53. ncbi request reprint New insights into the biology and advances in the management of multiple myeloma
    Jean Luc Harousseau
    Department of Hematology, University Hospital Hotel Dieu, Place Alexis Ricordeau, 44093 Nantes, France
    Best Pract Res Clin Haematol 20:569-70. 2007
  54. doi request reprint Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
    Philippe Moreau
    University Hospital, Nantes, France
    Blood 116:4777-82. 2010
    ..019). Lenalidomide 15 mg/d + M-dex is a new effective combination therapy in patients with newly diagnosed AL amyloidosis. This study is registered at www.clinicaltrials.gov as NCT00621400...
  55. doi request reprint Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy
    Pierre Joseph Royer
    INSERM, U601, Nantes, France Université de NANTES, Faculte de Medecine, Centre de Recherche en Oncologie, Nantes, France
    Exp Hematol 36:329-39. 2008
    ..The aim of our study was to assess, for vaccine preparation, generation of monocyte-derived DCs in AML patients after CT...
  56. ncbi request reprint Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I
    Thomas Gastinne
    Service d Hematologie Clinique, CHU, Nantes, France
    Eur J Haematol 79:297-304. 2007
    ..In this series, we demonstrated that a proliferation marker provides clear-cut additional survival prognostic information to b2m into the ISS model...
  57. doi request reprint Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC
    Patrice Chevallier
    Centre Hospitalier Universitaire CHU Hotel Dieu, Cellule de Promotion à la Recherche Clinique, CHU Hotel Dieu, Nantes, France
    J Clin Oncol 26:4940-3. 2008
    ..This retrospective multicenter study assessed the outcome of 51 patients with myeloid sarcoma (MS) who underwent allogeneic hematopoietic stem-cell transplantation (alloHSCT)...
  58. ncbi request reprint Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells
    Sophie Derenne
    Institut National de la Santé et de la Recherche Médicale Unité 463 Institut de Biologie, Nantes, France
    Blood 100:194-9. 2002
    ..As MM remains an incurable disease despite intensive chemotherapy, these results suggest that Mcl-1 antisense strategy rather than Bcl-2 antisense strategy could be of considerable importance in the treatment of MM...
  59. doi request reprint Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire
    Steven Le Gouill
    Hematology Department, University Hospital, Hotel Dieu, Nantes, France
    J Clin Oncol 26:2264-71. 2008
    ..Aggressive T-cell lymphomas (ATCLs) represent 10% to 15% of non-Hodgkin's lymphomas (NHLs) in adults. ATCLs show a worse prognosis than B-cell lymphomas...
  60. doi request reprint A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial
    Patrice Chevallier
    Service d Hematologie Clinique, CHU Hotel Dieu, Nantes, France
    Leuk Res 33:1124-6. 2009
    ..While no activity was seen in this phase II trial, the findings of the study do not rule out efficacy in subsets of AML with imatinib-sensitive Kit mutations...
  61. ncbi request reprint Stem cell transplantation in multiple myeloma (0, 1, or 2)
    Jean Luc Harousseau
    Department of Hematology, Hotel Dieu, Nantes, France
    Curr Opin Oncol 17:93-8. 2005
    ....
  62. doi request reprint Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group
    Caroline Bodet-Milin
    Service de Medecine Nucleaire, CHU de Nantes, Nantes, France
    Eur J Nucl Med Mol Imaging 37:1633-42. 2010
    ..This retrospective study investigated the value of FDG PET for initial staging and its prognostic impact on patients with mantle cell lymphoma (MCL)...
  63. ncbi request reprint CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia
    Patrice Chevallier
    Laboratoire d Hematologie, Institut de Biologie, Centre Hospitalier Universitaire, Nantes, France
    Br J Haematol 116:142-50. 2002
    ..In conclusion, CD38 expression and secondary 17p deletion are important poor prognostic indicators, especially in Binet stage A CLL...